Cassava Sciences | PTIE - Current Liabilities


Cassava Sciences reported $48.05M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Abbott USD 14.58B 1.14B Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
Cassava Sciences USD 48.05M 716K Sep/2025
Eisai JPY 378.25B 33.36B Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Geron USD 87.71M 23.43M Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Roche Holding CHF 28B 421M Dec/2025